health · 3 outlets · 3 linked reports
The First Lyme Disease Vaccine in Decades Passes Its Big Trial
AI-assisted: summaries and questions may be incomplete or incorrect. Verify important details with the linked original reporting.
Summary
- Pfizer and Valneva reported on March 23, 2026 that their Lyme disease vaccine candidate showed about 73-75% efficacy in ages 5 and up in the Phase 3 VALOR trial — the first Lyme vaccine progress in 24 years.
- The two-year study enrolled roughly 9,400 people across endemic areas of the US, Canada and Europe, and the shot was well tolerated.
- Pfizer plans to seek US and EU approval in 2026, with a possible 2027 launch — though fewer-than-expected cases meant one statistical benchmark was narrowly missed.
The question
A Lyme disease vaccine is finally within reach after decades of setbacks.
Open this story in Khali
Get Khali on the App Store